Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma
The purpose of this study is to provide treatment with nivolumab in combination with
ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have
unresectable or metastatic melanoma.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society